### **thermo**scientific

$$LR = \left(\frac{SD_C}{SD_D}\right) \cdot e^{-0.5\left[\left(\frac{\log 10 X - MD}{SD_D}\right)^2 - \left(\frac{\log 10 X}{SD_D}\right)^2\right]}$$

# Powerful and robust

B·R·A·H·M·S Fast Screen pre I plus: Risk calculation for prenatal screening




# B·R·A·H·M·S Fast Screen pre I plus

A modern, powerful, and robust clinical PNS software for 1st and 2nd trimester




Thermo Scientific™ B·R·A·H·M·S™ Fast Screen pre I plus is a CE marked software designed to ensure convenience of data entry, risk calculation and reporting for laboratories with both, low and high data throughput.




# Because quality matters

First trimester combined screening considers maternal characteristics, biomarkers such as PAPP-A and Free βhCG as well as ultrasound measurements such as Nuchal Translucency (NT) and Nasal Bone (NB).

The result of this risk assessment is provided as individual risk of a pregnant woman. It is essential, that the result is as reliable and accurate as possible. This can only be achieved by using the best available methods.







### Ultrasound

A correct determination of NT is very important for a correct risk calculation. It is recommended that a sonographer holds a certification of the Fetal Medicine Foundation (FMF) <sup>1</sup> or a corresponding local organization.



### **Biomarkers**

The biochemical assays Thermo Scientific B·R·A·H·M·S Free βhCG, PAPP-A and PIGF plus KRYPTOR™ fulfil the strict quality requirements of the FMF since 1999 and provide constantly the highest precision and stability data as proved by the UK NEQAS data.²



#### Software

B·R·A·H·M·S Fast Screen pre I plus offers first trimester algorithms that are based on the FMF data and are updated with recently published further improvements. The huge database ensures a statistically significant robustness.<sup>3</sup>

# High quality algorithms and stable medians ensure best results



# Trisomy 21, 18 and 13

The B·R·A·H·M·S Fast Screen pre I plus algorithm for first trimester combined screening is based on FMF risk calculation and published data.<sup>3,4,5</sup>

PAPP-A Free βhCG PIGF NT NB DVPI TR

Week of gestation ... 3

3

5

)

7

9

8

10

12

11

13

14


Pre-eclampsia

The B·R·A·H·M·S Fast Screen pre I plus algorithm for first trimester pre-eclampsia combines maternal characteristics, obstetrics history, biophysical markers and maternal serum biomarkers. The algorithm developed by the FMF was fitted on gestational age at the time of delivery with pre-eclampsia.

PAPP-A PIGF MAP UAPI

## Stable and robust medians guarantee a reliable risk calculation

The medians of the B·R·A·H·M·S biochemical markers Free βhCG, PAPP-A and PIGF <sup>8</sup>, which are included in the B·R·A·H·M·S Fast Screen pre I plus software, are extremely stable. The medians were established on over 220 000 healthy pregnancies. <sup>3</sup> A recalculation of medians and MoMs over the time is not required. <sup>9</sup>



## Trisomy 21 and 18

The B·R·A·H·M·S Fast Screen pre I plus second trimester algorithm allows calculation of risk for trisomies 21 and 18 with double test (AFP and hCG+\beta/Free \beta hCG).

**AFP** hCG+β / Free βhCG



15 17 18 19 20 16 21 22 23 24 25 ...

The AFP value indicates the fetal neural tube defect (NTD). **AFP** 

**DVPI** Ductus Venosus Pulsatility Index **MAP** Mean Arterial Pressure

Nasal Bone NB

Nuchal Translucency NT NTD Neural Tube Defects TR Tricuspid Regurgitation

**UAPI** Uterine Artery Pulsatility Index




Figure Distribution of the cumulative measurement of Free βhCG and PAPP-A of ~55 000 samples (blue bars) over a time period of 6 years compared to the predicted distribution (red curve)9

# B·R·A·H·M·S Fast Screen pre I plus

### More than just a risk calculation tool

B·R·A·H·M·S Fast Screen pre I plus contains various useful tools for data management, internal and external quality control, audits and statistics. Particular attention is paid to patient data security and traceability.



# Maximum data security and traceability: Fulfilling the requirements of a clinical software

- Software audit option for external quality control
- Internal audit trails to trace all actions
- Pop-up warnings if data is missing or out of range
- Validation of data before production of report
- All data are saved automatically
- 4 levels of users for data entry and management



## Easy and effective: Useful data management tools


- Statistic and audit reports
- Pregnancy outcome requests and follow-up information
- Database search tool
- Export data for statistics and research
- Printing reports one by one or in defined batches
- Printing, saving and sending reports automatically via email
- Possibility to keep extended patient data for record purposes

### **Additional benefits**


- 7 languages of interface, reports and user manuals (English, German, French, Spanish, Italian, Turkish, and Russian)
- Software trial version for 60 days
- Dedicated technical and scientific support



### Manual entry of patient data and connection to B·R·A·H·M·S KRYPTOR




### **Automatic** data transfer via Laboratory Information System (LIS)



### **thermo**scientific

Visit our online software demonstration fastscreen.world-of-biomarkers.com



<b>\( \)</b>	Biomarkers	
	B·R·A·H·M·S <b>AFP</b> KRYPTOR	Art. no.: 816.075
	B·R·A·H·M·S <b>Free βhCG</b> KRYPTOR	Art. no.: 809.075
	B·R·A·H·M·S <b>hCG+</b> β KRYPTOR	Art. no.: 841.050
	B·R·A·H·M·S <b>Inhibin A</b> KRYPTOR*	Art. no.: 850.075
	B·R·A·H·M·S <b>PAPP-A</b> KRYPTOR	Art. no.: 866.075
	B·R·A·H·M·S <b>PIGF plus</b> KRYPTOR**	Art. no.: 859.075
	B·R·A·H·M·S <b>sFlt-1</b> KRYPTOR**	Art. no.: 845.075
	B·R·A·H·M·S <b>uE3</b> KRYPTOR***	Art. no.: 803.075
<u>~</u>	Software	
	B·R·A·H·M·S <b>Fast Screen pre I plus</b>	Art. no.: 105750
o <sup>©</sup>	Instruments	
	B·R·A·H·M·S KRYPTOR GOLD	Art. no.: BMKSYS0201
	B·R·A·H·M·S KRYPTOR compact PLUS	Art. no.: 106172

#### References

- 1. https://fetalmedicine.org/training-n-certification/certificates-of-competence
- $2. \quad \text{Monthly UK NEQAS reports, February 2003} \text{September 2019} \\$
- 3. Wright D et al. Ultrasound Obstet Gynecol 2010; 36: 404-411
- 4. Kagan KO et al. Ultrasound Obstet Gynecol 2008; 31: 618-624
- 5. Nicolaides KH. Prenat Diagn 2011; 31: 7-15
- 6. Wright D et al. Fetal Diagn Ther 2012; 31: 87-93
- 7. O'Gorman N et al. Am J Obstet Gynecol 2016; 214(1): 103.e1-103.e12
- 8. Pandya P et al. Fetal Diagn Ther 2012; 32: 171-178
- Spencer K. Presentation on B-R-A-H-M-S KRYPTOR User Meeting, Cambridge, March 2007

**Clinical Diagnostics** 

Available on B·R·A·H·M·S KRYPTOR GOLD

Thermo Fisher Scientific B·R·A·H·M·S GmbH Neuendorfstr. 25 16761 Hennigsdorf/Germany

\*\*\* Available on B·R·A·H·M·S KRYPTOR, B·R·A·H·M·S KRYPTOR compact PLUS and B·R·A·H·M·S KRYPTOR GOLD

+49 (0)3302 883 0 +49 (0)3302 883 100 fax info.brahms@thermofisher.com www.thermoscientific.com/brahms

### Find out more at thermoscientific.com/brahms

Available on B·R·A·H·M·S KRYPTOR compact PLUS and B·R·A·H·M·S KRYPTOR GOLD

Products are CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.

© 2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B-R-A-H-M-S GmbH, a part of Thermo Fisher Scientific.

